Blepharospasm
Blepharospasm is a focal dystonia that causes involuntary contractions around the eyes, usually producing bilateral and synchronous eyelid closure. Frequent or sustained spasms can interrupt reading, walking, driving, work, and other daily activities; severe episodes may cause functional blindness even when the eyes themselves can see normally.
Botulinum toxin treatment aims to reduce disruptive eyelid closure while preserving enough eyelid movement and blinking to protect the ocular surface. This functional goal is different from softening facial lines for cosmetic purposes.
Similar-looking problems are not the same disorder
Section titled “Similar-looking problems are not the same disorder”| Presentation | Distinguishing context |
|---|---|
| Blepharospasm | Usually bilateral, synchronous involuntary eyelid closure caused by focal dystonia |
| Hemifacial spasm | Usually unilateral contractions involving muscles supplied by the facial nerve, often extending beyond the eyelids |
| Apraxia of eyelid opening | Difficulty initiating eyelid opening rather than forceful eyelid closure alone; it may coexist with blepharospasm |
| Reflex blinking or eyelid squeezing | Ocular irritation, dry eye, light sensitivity, or another surface problem may provoke increased blinking without primary dystonia |
| Tics | Blinking may be suppressible for a time and accompanied by an urge or other tic phenomena |
These distinctions affect diagnosis, target selection, expected benefit, and whether ocular-surface or neurological evaluation is needed. They should not be inferred from eyelid movement alone.
Current U.S. product scope
Section titled “Current U.S. product scope”| Product | U.S. blepharospasm scope | Important boundary |
|---|---|---|
| BOTOX (onabotulinumtoxinA) | Blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders, in patients aged 12 years and older | The label language includes a defined age threshold and disease context. |
| XEOMIN (incobotulinumtoxinA) | Blepharospasm in adults | The U.S. indication is adult-specific. |
| DYSPORT (abobotulinumtoxinA) | Blepharospasm is not listed among current U.S. indications | Published studies or authorization in another market do not create a U.S. indication. |
This matrix describes regulatory scope, not equivalence or a treatment ranking. The absence of a U.S. indication does not mean a product has never been studied or used for the condition; it means the current U.S. label does not authorize that indication.
Benefit is measured in function as well as spasm severity
Section titled “Benefit is measured in function as well as spasm severity”Treatment response can be assessed through:
- frequency and severity of involuntary eyelid closure
- time the eyes remain functionally open
- reading, mobility, driving, work, and other daily activities
- light sensitivity, discomfort, and patient-reported disability
- duration of useful benefit and the return of symptoms
- adverse effects such as eyelid droop, dry eye, visual disturbance, or facial weakness
Randomized evidence supports botulinum toxin type A over placebo for blepharospasm. An early example is Joseph Jankovic, M.D. and Janet Orman’s 1987 placebo-controlled study 🔗, which included 12 patients with blepharospasm. Comparative evidence is less suitable for declaring one formulation superior: studies combine different protocols, products, outcome measures, and sometimes related disorders, while potency units remain product-specific.
Eyelid anatomy creates a narrow therapeutic balance
Section titled “Eyelid anatomy creates a narrow therapeutic balance”The muscles around the eye participate in both unwanted closure and normal blinking. Excessive local weakening can cause eyelid ptosis or incomplete closure, while reduced blinking may worsen ocular-surface exposure. Baseline dry eye, eyelid position, facial nerve dysfunction, prior surgery, and the pattern of muscle involvement can all change risk.
Current BOTOX and XEOMIN labeling warns that treatment around the eyelids can reduce blinking and contribute to corneal exposure, epithelial injury, or ulceration. The XEOMIN label also identifies ectropion as a possible complication. New eye pain, marked redness, visual change, or inability to close the eye warrants prompt clinical assessment.
Class-wide warnings about distant spread of toxin effect also apply, including potentially serious swallowing or breathing difficulty. See How anatomy changes botulinum toxin interpretation, Dose interpretation, and Safety and adverse-effect interpretation.
Related topics
Section titled “Related topics”References
Section titled “References”- U.S. National Library of Medicine. BOTOX prescribing information 🔗.
- U.S. National Library of Medicine. XEOMIN prescribing information 🔗.
- U.S. National Library of Medicine. DYSPORT prescribing information 🔗.
- Cochrane. Botulinum toxin type A for people with involuntary eyelid closure, or blepharospasm 🔗.
- Ilic TV, et al. Efficacy and safety of botulinum toxin type A formulations in blepharospasm and hemifacial spasm: a systematic review and network meta-analysis 🔗. 2026.